logo
AcuityMD Expands Care Journeys Solution with Enhanced Physician Referral Networks to Increase Patient Access to MedTech Innovations

AcuityMD Expands Care Journeys Solution with Enhanced Physician Referral Networks to Increase Patient Access to MedTech Innovations

Business Wire28-04-2025
BOSTON--(BUSINESS WIRE)-- AcuityMD, the MedTech Intelligence Platform, today announced a new solution that will help MedTech companies and healthcare providers (HCPs) deliver new treatment options to more patients. Referral Pathways in AcuityMD Care Journeys provides comprehensive patient referral data so MedTech commercial teams can easily identify the physicians who can most benefit from their products and bring innovations to more patients.
Referral Pathways in AcuityMD Care Journeys provides comprehensive patient referral data so MedTech commercial teams can easily identify the physicians who can most benefit from their products and bring innovations to more patients
Share
AcuityMD Care Journeys, launched in October 2024, was designed to help MedTech companies demonstrate the improved clinical and financial outcomes their technology delivers for patients with complex diagnoses and treatment journeys – helping them drive product adoption with hospitals and physicians. Now, AcuityMD is expanding its solution with sophisticated, data-driven visualizations to empower MedTech companies to connect upstream referrers to the HCPs offering their differentiated treatments. It gives a more complete view of the care journey, enabling teams to better target their innovations and improve outcomes for more patients.
Supporting Overburdened Physicians
According to a 2024 survey, 80% of physicians report being overworked. An aging patient population and more patients with comorbidities (i.e., obesity plus diabetes, asthma, sleep apnea, and kidney disease), combined with a serious physician shortage, makes it difficult for providers to stay current on the latest medical innovations. At the same time, MedTech companies are developing new technologies, thanks to advances in AI, robotics, and digital, at an unprecedented clip – in fact, the industry is expected to grow to $800 billion by 2030.
The volume of innovation can overwhelm providers who are already feeling strained by high case volume, staffing challenges, and administrative responsibilities. They simply do not always have time to uncover the latest treatment options for their patients, nor research local doctors providing these new treatments and the outcomes patients are experiencing.
MedTech companies have attempted to bridge this gap by hosting regional and local educational events with HCPs, but information blind spots remain. Comprehensive referral data is often lacking because it only captures a patient's most recent encounter. MedTech companies struggle to find all relevant HCPs who impact the patient journey, causing some patients to miss out on more effective treatments simply due to a lack of physician awareness.
With AcuityMD's new Referral Pathways in Care Journeys, MedTech companies gain a comprehensive view of a provider's entire referral network to deliver better, consultative support.
'Referral Pathways takes MedTech commercialization to the next level, helping companies not only understand the clinical opportunity around an HCP, but also uncover new pathways for strategic referrals towards those HCPs,' said Megan Wilson, director of product management at AcuityMD. 'By identifying the doctors seeing the highest number of relevant patients and leveraging Referral Pathways, Care Journeys can help sales teams make smarter connections, and ultimately help ensure that patients receive the best possible care through the latest, most innovative treatments.'
Uncovering Opportunities for Improved Care
Referral Pathways goes beyond traditional referral data to uniquely map upstream HCPs diagnosing the specific conditions in the same location where HCPs offer a company's therapy. MedTech teams can leverage this to uncover referral connections that even the treating HCP didn't know existed. For example, Teleflex Incorporated, a global provider of medical technologies that offers solutions across therapy areas, including interventional urology, is leveraging Care Journeys to increase adoption of its minimally invasive UroLift(™) System.
'Over 14 million men in the U.S. are living with symptoms of BPH (enlarged prostate). We know their treatment journey is long, and only a small percentage (3%) elect to have a surgical intervention,' explained Anthony Parrillo, global vice president of marketing at Teleflex. 'Referral Pathways allows us to identify the healthcare providers diagnosing BPH most often in a given market, raise their awareness of the UroLift System procedure, and share with them the UroLift physician locator on our website. This new data from AcuityMD has been remarkable in helping us target more effectively and maximize our opportunity to deliver minimally invasive treatment.'
Referral Pathways in AcuityMD Care Journeys is now generally available on the AcuityMD MedTech intelligence platform. Learn more this week at industry conferences:
American Urological Association (AUA) Conference (April 26-29), where AcuityMD will be showcasing Care Journeys at booth #521.
Device Talks Boston, where AcuityMD's Megan Wilson and Teleflex's Anthony Parrillo are presenting on Wednesday, April 30, in room 161.
About AcuityMD
AcuityMD is the MedTech Intelligence Platform for more than 300 MedTech companies – including six of the top 10. Commercial leaders use AcuityMD to identify target markets, surface top opportunities, and grow their business. With customers ranging from pre-commercial to enterprise, AcuityMD is committed to delivering the right insights, enabling companies to understand where and how to sell faster to accelerate the adoption of medical technology.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Caliber Announces Confidential Submission of Draft Registration Statement for Proposed Initial Public Offering
Caliber Announces Confidential Submission of Draft Registration Statement for Proposed Initial Public Offering

Yahoo

timean hour ago

  • Yahoo

Caliber Announces Confidential Submission of Draft Registration Statement for Proposed Initial Public Offering

LEWISVILLE, Texas, July 25, 2025--(BUSINESS WIRE)--Caliber Holdings Inc. ("Caliber") today announced that it has confidentially submitted a draft registration statement on Form S-1 with the Securities and Exchange Commission (the "SEC") relating to the proposed initial public offering of its common stock. The number of shares to be offered and the price range for the proposed offering have not yet been determined. Caliber expects to use the proceeds from the offering for general corporate purposes, which may include the repayment of indebtedness. This news release is being made pursuant to and in accordance with Rule 135 under the Securities Act of 1933, as amended, and does not constitute an offer to sell or the solicitation of an offer to buy securities, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction. View source version on Contacts Media Relations: CaliberPR@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Rosen Law Firm Encourages Simulations Plus, Inc. Investors to Inquire About Securities Class Action Investigation
Rosen Law Firm Encourages Simulations Plus, Inc. Investors to Inquire About Securities Class Action Investigation

Business Wire

timean hour ago

  • Business Wire

Rosen Law Firm Encourages Simulations Plus, Inc. Investors to Inquire About Securities Class Action Investigation

NEW YORK--(BUSINESS WIRE)--Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Simulations Plus, Inc. (NASDAQ: SLP) resulting from allegations that Simulations Plus may have issued materially misleading business information to the investing public. So What: If you purchased Simulations Plus securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rosen Law Firm is preparing a class action seeking recovery of investor losses. What to do next: To join the prospective class action, go to or call Phillip Kim, Esq. toll-free at 866-767-3653 or email case@ for information on the class action. What is this about: On July 15, 2025, during market hours, Benzinga published an article entitled 'Simulations Plus Sees Weaker Demand Persist, Outlook Softens.' The article stated that Simulations Plus shares had declined 'following the release of [Simulations Plus'] third-quarter 2025 earnings report.' The article stated that Simulations Plus had reported sales of $20.4 million, representing a 10% year-over-year increase, but this fell short of the consensus estimate of $20.9 million.' Further, '[t]his miss followed preliminary third-quarter sales figures released in June, which were already lower than expectations at $19 million to $20 million, compared to a consensus of $22.78 million.' On this news, the price of Simulations Plus stock fell 25.75% on July 15, 2025. Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. At the time Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers. Follow us for updates on LinkedIn: on Twitter: or on Facebook: Attorney Advertising. Prior results do not guarantee a similar outcome.

Caliber Announces Confidential Submission of Draft Registration Statement for Proposed Initial Public Offering
Caliber Announces Confidential Submission of Draft Registration Statement for Proposed Initial Public Offering

Business Wire

timean hour ago

  • Business Wire

Caliber Announces Confidential Submission of Draft Registration Statement for Proposed Initial Public Offering

LEWISVILLE, Texas--(BUSINESS WIRE)--Caliber Holdings Inc. ('Caliber') today announced that it has confidentially submitted a draft registration statement on Form S-1 with the Securities and Exchange Commission (the 'SEC') relating to the proposed initial public offering of its common stock. The number of shares to be offered and the price range for the proposed offering have not yet been determined. Caliber expects to use the proceeds from the offering for general corporate purposes, which may include the repayment of indebtedness. This news release is being made pursuant to and in accordance with Rule 135 under the Securities Act of 1933, as amended, and does not constitute an offer to sell or the solicitation of an offer to buy securities, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store